ATE515505T1 - Heterocyclische fxr-bindende verbindungen - Google Patents

Heterocyclische fxr-bindende verbindungen

Info

Publication number
ATE515505T1
ATE515505T1 AT07801977T AT07801977T ATE515505T1 AT E515505 T1 ATE515505 T1 AT E515505T1 AT 07801977 T AT07801977 T AT 07801977T AT 07801977 T AT07801977 T AT 07801977T AT E515505 T1 ATE515505 T1 AT E515505T1
Authority
AT
Austria
Prior art keywords
compounds
binding compounds
fxr binding
heterocyclic
fxr
Prior art date
Application number
AT07801977T
Other languages
English (en)
Inventor
Claus Kremoser
Ulrich Deuschle
Ulrich Abel
Andreas Schulz
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Application granted granted Critical
Publication of ATE515505T1 publication Critical patent/ATE515505T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07801977T 2006-08-29 2007-08-29 Heterocyclische fxr-bindende verbindungen ATE515505T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84091206P 2006-08-29 2006-08-29
EP06018024A EP1894928A1 (de) 2006-08-29 2006-08-29 Fxr bindende heterocyclische verbindungen
PCT/EP2007/007556 WO2008025539A1 (en) 2006-08-29 2007-08-29 Heterocyclic fxr binding compounds

Publications (1)

Publication Number Publication Date
ATE515505T1 true ATE515505T1 (de) 2011-07-15

Family

ID=37663275

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07801977T ATE515505T1 (de) 2006-08-29 2007-08-29 Heterocyclische fxr-bindende verbindungen

Country Status (4)

Country Link
US (1) US8193192B2 (de)
EP (2) EP1894928A1 (de)
AT (1) ATE515505T1 (de)
WO (1) WO2008025539A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101883769B (zh) 2007-12-04 2012-08-08 弗·哈夫曼-拉罗切有限公司 异噁唑-吡嗪衍生物
US7902201B2 (en) 2007-12-04 2011-03-08 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
EP2128158A1 (de) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclische Cyclopropyl-substituierte FXR-bindende Verbindungen
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US20100280019A1 (en) 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles
AU2010244545A1 (en) * 2009-05-05 2011-10-13 F. Hoffmann-La Roche Ag Isoxazole-pyridazine derivatives
SG175333A1 (en) 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-pyrazole derivatives
BRPI1013844A2 (pt) 2009-05-05 2016-04-12 Hoffmann La Roche derivados de piridina-isoxazol
CN102414208B (zh) 2009-05-05 2014-11-05 霍夫曼-拉罗奇有限公司 作为用于认知性障碍的治疗中的gaba a受体逆激动剂的异*唑-噻唑衍生物
CN102414203B (zh) * 2009-05-07 2014-11-26 弗·哈夫曼-拉罗切有限公司 用作gaba调节剂的异*唑-吡啶衍生物
EP2289883A1 (de) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Neue Aktivitätsmodulationsverbindungen für FXR- (NR1H4)
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
WO2012007869A2 (en) * 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2545964A1 (de) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
AU2013283487C1 (en) 2012-06-26 2018-01-18 Saniona Aps A phenyl triazole derivative and its use for modulating the GABAA receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CA2876780A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
SI3043865T1 (sl) 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
WO2016049069A1 (en) 2014-09-24 2016-03-31 Gilead Sciences, Inc. Methods of treating liver disease
EP3006939A1 (de) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidinreiches Glycoprotein als Marker zur hepatischen Farnesoid-X-Aktivierung
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034501A1 (de) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxyhaltige FXR (NR1H4) modulierende Verbindungen
EP3034499A1 (de) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Neuartige FXR (NR1H4) modulierende Verbindungen
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
SI3277286T1 (sl) 2015-03-31 2021-09-30 Enanta Pharmaceuticals, Inc. Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
KR102079844B1 (ko) 2016-09-20 2020-02-20 가톨릭대학교 산학협력단 담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN109862887B (zh) 2016-11-03 2021-09-10 广东东阳光药业有限公司 一种金刚烷胺类化合物的晶型、组合物及其用途
BR112019017312A2 (pt) 2017-02-21 2020-04-14 Genfit combinação de um agonista de ppar com um agonista de fxr
EP4424364A2 (de) 2017-03-28 2024-09-04 Gilead Sciences, Inc. Verfahren zur behandlung von lebererkrankungen
JP2020515564A (ja) 2017-03-30 2020-05-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
PT3612520T (pt) 2017-04-12 2022-01-06 Il Dong Pharma Derivados de isoxazol como agonistas de recetores nucleares e utilizações dos mesmos
EP3704107B1 (de) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Multizyklische verbindungen als farnesoid-x-rezeptormodulatoren
JP7264906B2 (ja) 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
EA202091084A1 (ru) 2017-11-01 2020-08-13 Бристол-Маерс Сквибб Компани Алкеновые спироциклические соединения как модуляторы фарнезоидных x-рецепторов
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
HUE065889T2 (hu) 2019-01-15 2024-06-28 Gilead Sciences Inc Izoxazol vegyület mint FXR agonista és az azt tartalmazó gyógyszerészeti készítmények
EP3927683A1 (de) 2019-02-19 2021-12-29 Gilead Sciences, Inc. Feste formen von fxr-agonisten
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
EP3972695A1 (de) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituierte exo-methylen-oxindole als hpk1/map4k1-inhibitoren
EP3976049A1 (de) 2019-05-30 2022-04-06 Intercept Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen mit einem fxr-agonisten und ein fibrat zur verwendung bei der behandlung von cholestatischer lebererkrankung
WO2021009332A1 (en) 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
AU2021207253A1 (en) 2020-01-15 2022-06-09 Centre National De La Recherche Scientifique Use of FXR agonists for treating an infection by hepatitis D virus
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN114315815B (zh) * 2020-10-12 2024-07-19 甘莱制药有限公司 用于调节fxr活性的化合物及其应用
AU2022209084A1 (en) 2021-01-14 2023-08-10 Centre Leon Bérard Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
EP4329761A1 (de) 2021-04-28 2024-03-06 ENYO Pharma Starke potenzierung von tlr3-agonisten-effekten mit fxr-agonisten als kombinierte behandlung
CN114807224B (zh) * 2022-04-25 2023-09-29 中国人民解放军军事科学院军事医学研究院 一种可视化斑马鱼胆汁酸代谢模型的构建方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4219247A1 (de) * 1992-06-12 1993-12-16 Bayer Ag Verwendung von 3-arylsubstituierten 5-Alkyl-isoxazol-4-carbonsäurederivaten zur Bekämpfung von Endoparasiten, neue 3-arylsubstituierte 5-Alkyl-isoxazol-4-carbonsäurederivate und Verfahren zu ihrer Herstellung
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
AU8150398A (en) 1997-06-19 1999-01-04 Du Pont Pharmaceuticals Company Inhibitors of factor xa with a neutral p1 specificity group
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
DE60131967D1 (de) * 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
JP2006515838A (ja) * 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
CA2564355C (en) * 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
US8106077B2 (en) * 2006-05-24 2012-01-31 Eli Lilly And Company Compounds and methods for modulating FXR

Also Published As

Publication number Publication date
US8193192B2 (en) 2012-06-05
EP1894928A1 (de) 2008-03-05
WO2008025539A1 (en) 2008-03-06
EP2066663B1 (de) 2011-07-06
US20100210660A1 (en) 2010-08-19
EP2066663A1 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
ATE515505T1 (de) Heterocyclische fxr-bindende verbindungen
ATE555105T1 (de) Heterocyclische fxr-bindende verbindungen
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
NO20091599L (no) Kjemiske forbindelser
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
EA200900066A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
TW200628154A (en) Organic compounds
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
NO20091626L (no) MGLUR5-modulatorer
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
TW200800997A (en) Chemical compounds
NO20055688L (no) Organiske forbindelser
BRPI0519292A2 (pt) compostos orgÂnicos
TW200702330A (en) 3,4,5-Substituted piperidines
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties